Mesoblast (MESO) Other Non-Current Liabilities (2021 - 2026)
Mesoblast (MESO) posted Other Non-Current Liabilities of $14.2 million for Q4 2025, up 147.59% sequentially from $5.7 million in Q2 2025, and down 48.59% YoY from $27.6 million in Q4 2024.
Analysis
Mesoblast (MESO) Other Non-Current Liabilities (2021 - 2026) Analysis & Trends
Mesoblast has reported Other Non-Current Liabilities for 11 years, with the latest figure at $14.2 million in Q4 2025.
- Quarterly Other Non-Current Liabilities fell 48.59% year-over-year to $14.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $14.2 million (down 48.59% YoY) and the FY2025 annual result came in at $5.7 million, up 23.18% from the prior year.
- Other Non-Current Liabilities climbed to $14.2 million in Q4 2025 per MESO's latest filing, from $5.7 million in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $27.6 million in Q4 2024 and troughed at $2.2 million in Q2 2022.
- A 5-year average of $15.2 million and a median of $17.7 million in 2022 frame the typical range for Other Non-Current Liabilities.
- The sharpest annual moves came in 2023 and 2025: Other Non-Current Liabilities jumped 148.33% in 2023, then slumped 48.59% in 2025.
- Over 5 years, Other Non-Current Liabilities stood at $22.3 million in 2021, then declined by 19.9% to $17.9 million in 2022, then dropped by 4.37% to $17.1 million in 2023, then surged by 61.47% to $27.6 million in 2024, then plunged by 48.59% to $14.2 million in 2025.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $14.2 million, $5.7 million, and $27.6 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Mesoblast | 2.24 Bn | 2.14 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 8.91 Mn |
| Dec 31, 2025 | 14.17 Mn |
| Jun 30, 2025 | 5.72 Mn |
| Dec 31, 2024 | 13.44 Mn |
| Jun 30, 2024 | 4.65 Mn |
| Dec 31, 2023 | 992,000.00 |
| Jun 30, 2023 | 5.43 Mn |
| Mar 31, 2023 | 4.45 Mn |
| Dec 31, 2022 | 3.93 Mn |
| Sep 30, 2022 | 2.59 Mn |
| Jun 30, 2022 | 2.19 Mn |
| Mar 31, 2022 | 5.03 Mn |
| Dec 31, 2021 | 6.06 Mn |